TRUSTEES UNIV PA is a generic drug manufacturer focused on Oncology, Neurology.
TRUSTEES UNIV PA's Key Drugs
TRUSTEES UNIV PA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
TRUSTEES UNIV PA's Recent FDA Approvals
New NDA/BLA approvals for TRUSTEES UNIV PA over the last two years — novel drugs only, excluding generics and label supplements.
TRUSTEES UNIV PA's Therapeutic Areas
TRUSTEES UNIV PA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TRUSTEES UNIV PA's Top Competitors
TRUSTEES UNIV PA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TRUSTEES UNIV PA Pipeline Snapshot
Active clinical trials for TRUSTEES UNIV PA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2014-10-29
- Latest
- 2014-10-29
- Applications
- 1